Therefore, this makes sense to choose RIPK2 as a candidate target for OC, as RIPK2 inhibitors could be used in combination with chemotherapy agents to grapple with potential drug resistance and significantly ameliorate the original immune microenvironment that promotes tumor progression. The gene discussed is RIPK2; the disease is neoplasm.